Benzoyl Peroxide | Bepio | CD-1579 | CAS#94-36-0 | Bactericidal Agent

Benzoyl Peroxide
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329303

CAS#: 94-36-0

Description: Benzoyl Peroxide, also known as Bepio and CD-1579, is a bactericidal agent, peroxide derivative that has been used topically for burns and as a dermatologic agent in the treatment of acne and poison ivy dermatitis. Benzoyl Peroxide is used also as a bleach in the food industry.

Chemical Structure

Benzoyl Peroxide

CAS# 94-36-0

Instruction

Theoretical Analysis

MedKoo Cat#: 329303
Name: Benzoyl Peroxide
CAS#: 94-36-0
Chemical Formula: C14H10O4
Exact Mass: 242.06
Molecular Weight: 242.230
Elemental Analysis: C, 69.42; H, 4.16; O, 26.42

Price and Availability

Size	Price	Availability	Quantity
50g	USD 285	2 weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Benzoyl Peroxide; CD-1579; M-6050; CD 1579; M 6050; CD1579; M6050; Bepio; NeoBenz

IUPAC/Chemical Name: benzoic peroxyanhydride

InChi Key: OMPJBNCRMGITSC-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H10O4/c15-13(11-7-3-1-4-8-11)17-18-14(16)12-9-5-2-6-10-12/h1-10H

SMILES Code: O=C(OOC(C1=CC=CC=C1)=O)C2=CC=CC=C2

Appearance: Solid powder

Purity: 75% (wetted with 25% water)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 242.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Lamel SA, Sivamani RK, Rahvar M, Maibach HI. Evaluating clinical trial design:
systematic review of randomized vehicle-controlled trials for determining
efficacy of benzoyl peroxide topical therapy for acne. Arch Dermatol Res. 2015
Nov;307(9):757-66. doi: 10.1007/s00403-015-1568-9. Review. PubMed PMID: 26048131.

2: Vaccaro M, Guarneri F, Borgia F, Pollicino A, Altavilla G, Cannavò SP.
Efficacy, tolerability and impact on quality of life of clindamycin phosphate and
benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in
patients with metastatic colorectal cancer. J Dermatolog Treat.
2016;27(2):148-52. doi: 10.3109/09546634.2015.1086478. PubMed PMID: 26313697.

3: Smith TJ, Foegeding EA, Drake M. Sensory and Functionality Differences of Whey
Protein Isolate Bleached by Hydrogen or Benzoyl Peroxide. J Food Sci. 2015
Oct;80(10):C2153-60. doi: 10.1111/1750-3841.13000. PubMed PMID: 26317318.

4: Smith TJ, Gerard PD, Drake MA. Effect of temperature and concentration on
benzoyl peroxide bleaching efficacy and benzoic acid levels in whey protein
concentrate. J Dairy Sci. 2015 Nov;98(11):7614-27. doi: 10.3168/jds.2015-9890.
PubMed PMID: 26364115.

5: Weiss J, Stein Gold L, Leoni M, Rueda MJ, Liu H, Tanghetti E. Customized
Single-agent Therapy Management of Severe Inflammatory Acne: A Randomized,
Double-blind, Parallel-group, Controlled Study of a New Treatment--Adapalene
0.3%-Benzoyl Peroxide 2.5% Gel. J Drugs Dermatol. 2015 Dec;14(12):1427-35. PubMed
PMID: 26659936.

6: Kircik LH. The role of benzoyl peroxide in the new treatment paradigm for
acne. J Drugs Dermatol. 2013 Jun 1;12(6):s73-6. PubMed PMID: 23839205.

7: Morimoto H, Kikukawa Y, Murakami N. [Pharmacological profiles and clinical
effects of benzoyl peroxide gel as treatments for acne vulgaris]. Nihon
Yakurigaku Zasshi. 2015 Oct;146(4):225-32. doi: 10.1254/fpj.146.225. Japanese.
PubMed PMID: 26656967.

8: Kawashima M, Hashimoto H, Alio Sáenz AB, Ono M, Yamada M. Is benzoyl peroxide
3% topical gel effective and safe in the treatment of acne vulgaris in Japanese
patients? A multicenter, randomized, double-blind, vehicle-controlled,
parallel-group study. J Dermatol. 2014 Sep;41(9):795-801. doi:
10.1111/1346-8138.12580. PubMed PMID: 25132461.

9: Rehman K, Tan CM, Zulfakar MH. Development and in-vitro characterization of
fish oil oleogels containing benzoyl peroxide and salicylic acid as keratolytic
agents. Drug Res (Stuttg). 2014 Mar;64(3):159-65. doi: 10.1055/s-0033-1355351.
PubMed PMID: 24026957.

10: Bircher A, Friederich NF, Seelig W, Scherer K. Allergic complications from
orthopaedic joint implants: the role of delayed hypersensitivity to benzoyl
peroxide in bone cement. Contact Dermatitis. 2012 Jan;66(1):20-6. doi:
10.1111/j.1600-0536.2011.01996.x. PubMed PMID: 22085108.

11: Keating GM. Adapalene 0.1%/benzoyl peroxide 2.5% gel: a review of its use in
the treatment of acne vulgaris in patients aged ≥ 12 years. Am J Clin Dermatol.
2011 Dec 1;12(6):407-20. doi: 10.2165/11208170-000000000-00000. Review. PubMed
PMID: 21967116.

12: Baumann LS, Oresajo C, Yatskayer M, Dahl A, Figueras K. Comparison of
clindamycin 1% and benzoyl peroxide 5% gel to a novel composition containing
salicylic acid, capryloyl salicylic acid, HEPES, glycolic acid, citric acid, and
dioic acid in the treatment of acne vulgaris. J Drugs Dermatol. 2013
Mar;12(3):266-9. PubMed PMID: 23545907.

13: Dhawan SS, Gwazdauskas J. Clindamycin phosphate 1.2%-benzoyl peroxide (5% or
2.5%) plus tazarotene cream 0.1% for the treatment of acne. Cutis. 2013
Feb;91(2):99-104. PubMed PMID: 23513559.

14: Leyden JJ. Randomized, phase 2, dose-ranging study in the treatment of
rosacea with encapsulated benzoyl peroxide gel. J Drugs Dermatol. 2014
Jun;13(6):685-8. PubMed PMID: 24918558.

15: El-Latif AA, Hassan FA, Elshahed AR, Mohamed AG, Elsaie ML. Intense pulsed
light versus benzoyl peroxide 5% gel in treatment of acne vulgaris. Lasers Med
Sci. 2014 May;29(3):1009-15. doi: 10.1007/s10103-013-1440-0. PubMed PMID:
24114421.

Your view history

Benzoyl Peroxide featured